Updated on 25 May 2012
Sunovion has acknowledged that the two Mylan patents are valid, enforceable and infringed by Sunovion's Brovana product
Singapore: Mylan Specialty, which was formerly known as Dey Pharma, entered into a deal with Sunovion Pharmaceuticals, to resolve the patent litigation relating to Sunovion's Brovana product.
The US District Court for the Southern District of New York's final judgment and order noted that the parties entered into a settlement and license agreement and that Sunovion, which was previously called Sepracor Inc, acknowledged that two Mylan patents are valid, enforceable and infringed by Sunovion's Brovana product. The patents are set to expire on June 22, 2021. The terms of the parties' agreement, however, are confidential.
Ms Heather Bresch, CEO, Mylan, said that, "We are pleased with this settlement and remain confident in the intellectual property protecting Perforomist, as well as our combination product for the treatment of chronic obstructive pulmonary disease (COPD), which is presently in development. We believe this settlement and judgment by the court further strengthens the potential of our Specialty franchise and its portfolio of products."